Immediate Evaluation and Management
A child presenting with fever and a non-blanching rash on the lower legs requires urgent assessment for invasive meningococcal disease, with immediate parenteral antibiotics administered if the diagnosis is suspected, followed by urgent hospital referral—do not delay treatment for investigations. 1
Risk Stratification Based on Clinical Presentation
The critical first step is determining whether this represents early meningococcal disease versus a benign viral illness. The location and extent of the petechial rash is diagnostically crucial:
High-Risk Features (Treat Immediately)
- Petechiae extending beyond the distribution of the superior vena cava (i.e., not confined to face/upper chest) 1
- Purpuric rash (larger non-blanching lesions) 1
- Ill appearance, shock signs, or hemodynamic instability 1, 2
- Cold extremities, abnormal skin color, delayed capillary refill 1, 2
- Short interval between fever onset and rash (median 3.5 hours in invasive bacterial infection vs 24 hours in benign illness) 3
- Short time from fever to ED presentation (13.5 hours vs 24 hours) 3
Lower-Risk Features
- Petechiae confined to distribution of superior vena cava (face, neck, upper chest only) 2
- Well-appearing child with favorable clinical status during observation 3
- Longer interval between fever and rash onset 3
Immediate Management Algorithm
Step 1: Initial Assessment (Do Not Delay)
Evaluate for:
- Fever with lethargy, irritability, vomiting, headache, photophobia
- Neck stiffness, positive Kernig's or Brudzinski's signs
- In infants: poor feeding, high-pitched cry, full fontanelle
- Leg pain (associated with developing meningococcal disease) 1
- Signs of shock: tachycardia, hypotension, prolonged capillary refill
Step 2: Treatment Decision
If ANY high-risk features present:
- Administer parenteral antibiotics immediately (intramuscular benzylpenicillin out of hospital) 1
- Do not delay for investigations 1
- Arrange urgent hospital transfer 1
If petechiae confined to superior vena cava distribution AND well-appearing:
- Consider outpatient management with close follow-up 2
- Blood culture and C-reactive protein may guide decision 2
Step 3: Hospital-Based Evaluation
For children requiring admission:
- Blood cultures before antibiotics if possible, but do not delay antibiotics 1
- Complete blood count, inflammatory markers (CRP, procalcitonin) 3
- Note: CRP >6 mg/L is poorly correlated with serious illness alone 4, but significantly elevated values support IBI diagnosis 3
- Lumbar puncture if meningitis suspected and no contraindications 1
Step 4: Definitive Treatment
- Parenteral dexamethasone (0.15 mg/kg every 6 hours) with or within 24 hours of first antibiotic dose for bacterial meningitis, continue for 4 days 1
- Early senior clinician review (experienced clinician assessment is superior to laboratory tests) 1
- Early discussion with pediatric intensive care if progressive disease 1
Critical Pitfalls to Avoid
Sending the child home at first presentation: Half of children with meningococcal disease are initially sent home 1. Arrange interval reassessment for any febrile child with non-specific symptoms 1.
Waiting for investigations before antibiotics: Most deaths occur in the first 24 hours 1. Treatment must not be delayed.
Misdiagnosing as gastroenteritis: Children may present with fever, diarrhea, vomiting but without rash initially 1.
Dismissing blanching rashes: Some children present with blanching rashes that later become non-blanching 1.
Over-reliance on CRP alone: ESR >50 mm/h, ill appearance, shivering, lethargy, back rigidity, and prolonged capillary refill are more strongly associated with serious illness 4.
Evidence Context
Recent data shows the incidence of invasive bacterial infection in well-appearing children with fever and petechiae is lower than historically reported (1.5%) 3, with only 8 of 10 cases being meningococcal disease 3. However, the mortality risk when meningococcal disease is present remains high, justifying aggressive early treatment when clinical suspicion exists. Children with favorable clinical status during ED observation have significantly lower IBI risk (0.5% vs 16.7% with unfavorable status) 3.
Follow-Up Considerations
After treatment, assess for potential morbidities including hearing loss, neurological complications, psychiatric/behavioral problems, bone/joint complications, and post-traumatic stress disorder 1. Offer meningococcal C vaccine before hospital discharge 1.